GIPR and obesity disorder: The treatment of obesity has been transformed by the food and drug administration approval of incretin‐based therapies (i.e., those targeting glucagon‐like peptide 1 (GLP‐1) and gastric inhibitory polypeptide receptors) for the treatment of obesity.